{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.3","upperLimit":"31.0","value":"21.9"},{"groupId":"OG001","lowerLimit":"13.6","upperLimit":"19.9","value":"17.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Defined as time from randomization to death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"35.9 months","title":"Overall Survival (OS) at Time of Primary Analysis","type":"SECONDARY","unitOfMeasure":"months"}